Kennedy pushes peptide access as FDA panel weighs compounding route

An FDA advisory panel appointed by Health Secretary RFK Jr. recommended allowing licensed compounding pharmacies to produce several peptides with prescriptions, signaling a shift away from the FDA’s caution over safety and efficacy. Supporters argue it would curb a thriving unregulated market and expand patient access via providers, while critics warn it could bypass formal FDA review and safety safeguards. The final decision remains with the FDA, though Kennedy has authority to overrule agency conclusions, potentially reshaping the peptide market and care options.